{"id":"W4212977599","doi":"10.1200/jco.2022.40.6_suppl.011","title":"PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Hazard ratio; Clinical endpoint; Placebo; Androgen deprivation therapy; Abiraterone acetate; Oncology; Interim analysis; Progression-free survival; Prednisone; Olaparib; Confidence interval; Docetaxel; Randomized controlled trial; Urology; Androgen receptor; Cancer; Chemotherapy; Pathology; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009543074,0.001382283,0.001446775,0.0005100768,0.0003363807,0.001015858,0.001118986,0.001064148,0.01101583],"category_scores_gemma":[0.00102695,0.0005076886,0.0009583547,0.0003990079,0.0007130077,0.0007903791,0.0004848403,0.002474468,0.001332474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00072213,"about_ca_system_score_gemma":0.001326831,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006411343,"about_ca_topic_score_gemma":0.002001614,"domain_scores_codex":[0.9997818,0.0001072321,0.000009049229,0.00003681444,0.00002825818,0.00003690749],"domain_scores_gemma":[0.9994423,0.0001253142,0.0001514344,0.00002484323,0.00003111911,0.000225042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9408038,0.0101262,0.0008618911,0.001161367,0.0006136665,0.0001084477,0.00006274889,0.0007370679,0.005995193,0.0002620553,0.003067775,0.03619974],"study_design_scores_gemma":[0.9139296,0.08158386,0.001257518,0.00005320689,0.0001966339,0.0001057546,0.00002319727,0.000390284,0.0006232603,0.0001677338,0.001657,0.00001193103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9683649,0.007852945,0.001285891,0.001428644,0.000519822,0.00754836,0.006096329,0.0004463633,0.006456719],"genre_scores_gemma":[0.9614868,0.005101479,0.003011812,0.002195077,0.0004265804,0.01061908,0.006859811,0.00006059632,0.01023877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01101583,"threshold_uncertainty_score":0.03685164,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1667641359119953,"score_gpt":0.4970009066430789,"score_spread":0.3302367707310836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}